AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 347857 — intervention group
Group type: COMPARATOR
Intervention: Combined oestrogen/androgen compound
Number of subjects: 0
Study 347857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31629880 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Resistance Training (IRT)
Number of subjects: 28
Study 31629880 — intervention group
Group type: COMPARATOR
Intervention: Sham Control (PLA)
Number of subjects: 28
Study 31295393 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office technique (40%HP, Opalescence Boost) in three sessions (40 minutes each)
Number of subjects: 75
Study 31295393 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home technique (10%HP, Opalescence GO) for 15 days (1 hour per day)
Number of subjects: 75
Study 31295393 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined technique (initial session with 40%HP, followed by 10%HP for 15 days)
Number of subjects: 75
Study 31295393 — intervention group
Group type: COMPARATOR
Intervention: All techniques (at-home, in-office, combined)
Number of subjects: 75
Study 31295393 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office technique
Number of subjects: 75
Study 28091532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibudilast (50 mg b.i.d.)
Number of subjects: 24
Study 28091532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 26987135 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol succinate (59.1 ± 12.1 mg/d)
Number of subjects: 100
Study 26987135 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine (12.1 ± 4.6 mg/d)
Number of subjects: 100
Study 26987135 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Metoprolol and Ivabradine)
Number of subjects: 100
Study 23959319 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin with higher maximum concentrations of drug in serum (Cmax) and large, infrequent doses
Number of subjects: 2
Study 23959319 — intervention group
Group type: COMPARATOR
Intervention: Micafungin with lower doses
Number of subjects: 2
Study 21120743 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxic gas (99.5 ± 0.2 % F(I)O(2))
Number of subjects: 7
Study 21120743 — intervention group
Group type: COMPARATOR
Intervention: Control (no external supplementation)
Number of subjects: 7
Study 19961366 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy without subcostal and lateral trocars (LCWSL)
Number of subjects: 60
Study 19961366 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (CLC)
Number of subjects: 60
Study 17276446 — intervention group
Group type: EXPERIMENTAL
Intervention: SVC segmental ostial isolation (SOI)
Number of subjects: 95
Study 17276446 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary vein (PV) segmental ostial isolation (SOI)
Number of subjects: 95
Study 15157139 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention involving picking referents of novel nouns from pairs of familiar objects (Experiments 1 and 3)
Number of subjects: 0
Study 15157139 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention involving teaching subordinate names for familiar objects (Experiment 2)
Number of subjects: 0
Study 15157139 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhyme-sensitization procedure (Experiment 3)
Number of subjects: 0
Study 15157139 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment impact
Number of subjects: 0
Study 11204052 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural opioid (fentanyl)
Number of subjects: 10
Study 11204052 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural local anesthetic (bupivacaine)
Number of subjects: 10
Study 11204052 — intervention group
Group type: COMPARATOR
Intervention: Control (no opioids)
Number of subjects: 10
Study 9510492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 66
Study 9510492 — intervention group
Group type: COMPARATOR
Intervention: Felodipine
Number of subjects: 66
Study 8032803 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance (MR) imaging
Number of subjects: 20
Study 8032803 — intervention group
Group type: COMPARATOR
Intervention: Scintigraphic (SC) volume estimations
Number of subjects: 20
Study 3281060 — intervention group
Group type: EXPERIMENTAL
Intervention: Alizapride 50 mg
Number of subjects: 90
Study 3281060 — intervention group
Group type: EXPERIMENTAL
Intervention: Alizapride 100 mg
Number of subjects: 90
Study 3281060 — intervention group
Group type: EXPERIMENTAL
Intervention: Alizapride 200 mg
Number of subjects: 90
Study 3281060 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 90
Study 29222619 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural sleep medicine (BSM) intervention targeting physical activity and eating behaviour (10 individual sessions with a dietician and a physiotherapist).
Number of subjects: 86
Study 29222619 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG; CPAP and advice about weight loss).
Number of subjects: 86
Study 29222619 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural sleep medicine (BSM) intervention targeting physical activity and eating behaviour.
Number of subjects: 86
Study 28314618 — intervention group
Group type: EXPERIMENTAL
Intervention: Drop punt kicking
Number of subjects: 36
Study 28314618 — intervention group
Group type: COMPARATOR
Intervention: Control (10min of sitting)
Number of subjects: 36
Study 25522824 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-modulated steady-state visual evoked potentials (FM-SSVEPs) with carrier frequencies of 20Hz and above
Number of subjects: 0
Study 25522824 — intervention group
Group type: COMPARATOR
Intervention: Sinusoidally evoked SSVEPs
Number of subjects: 0
Study 25522824 — intervention group
Group type: COMPARATOR
Intervention: Rectangularly evoked SSVEPs
Number of subjects: 0
Study 23381968 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 23381968 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 0
Study 21421501 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump coronary artery bypass grafting (CPB)
Number of subjects: 48
Study 21421501 — intervention group
Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass grafting (non-CPB)
Number of subjects: 48
Study 19453846 — intervention group
Group type: EXPERIMENTAL
Intervention: MYC gene amplification
Number of subjects: 236
Study 17142063 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen ER 3900 mg
Number of subjects: 483
Study 17142063 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen ER 1950 mg
Number of subjects: 483
Study 17142063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483
Study 15135695 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 496
Study 15135695 — intervention group
Group type: COMPARATOR
Intervention: Silicon carbon-coated stent implantation
Number of subjects: 496
Study 11294665 — intervention group
Group type: EXPERIMENTAL
Intervention: vCP205 plus gp120
Number of subjects: 435
Study 11294665 — intervention group
Group type: COMPARATOR
Intervention: vCP205 alone
Number of subjects: 435
Study 11294665 — intervention group
Group type: EXPERIMENTAL
Intervention: vCP205 with or without gp120
Number of subjects: 435
Study 9710686 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1/0.06 mg/kg r-hirudin (bolus/infusion per hour over 48 h)
Number of subjects: 143
Study 9710686 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2/0.1 mg/kg r-hirudin (bolus/infusion per hour over 48 h)
Number of subjects: 143
Study 9710686 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4/0.15 mg/kg r-hirudin (bolus/infusion per hour over 48 h)
Number of subjects: 143
Study 9710686 — intervention group
Group type: EXPERIMENTAL
Intervention: All dosage groups
Number of subjects: 143
Study 7800117 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trioleate and trierucate oils (Lorenzo's Oil)
Number of subjects: 14
Study 7800117 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated ALD patients)
Number of subjects: 14
Study 2647535 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% ketanserin ointment
Number of subjects: 23
Study 2647535 — intervention group
Group type: COMPARATOR
Intervention: Placebo (polyethylene glycol base)
Number of subjects: 23
Study 31504116 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Nordic diet (HND)
Number of subjects: 0
Study 31504116 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CD)
Number of subjects: 0
Study 29179781 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat yogurt (339 g daily for 9 weeks)
Number of subjects: 60
Study 29179781 — intervention group
Group type: COMPARATOR
Intervention: Control (soya pudding 324 g daily for 9 weeks)
Number of subjects: 60
Study 26069170 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (120 mg/day)
Number of subjects: 46
Study 26069170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 22887465 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive chemoradiotherapy (CRT)
Number of subjects: 81
Study 22887465 — intervention group
Group type: COMPARATOR
Intervention: Esophagectomy
Number of subjects: 81
Study 21727299 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation-depletion group
Number of subjects: 61
Study 21727299 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study 19368788 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1mL intradermal influenza vaccine
Number of subjects: 197
Study 19368788 — intervention group
Group type: COMPARATOR
Intervention: 0.5mL intramuscular influenza vaccine
Number of subjects: 197
Study 16752244 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective intravaginal electrical stimulation (IES)
Number of subjects: 40
Study 16752244 — intervention group
Group type: COMPARATOR
Intervention: Sham intravaginal electrical stimulation (IES)
Number of subjects: 40
Study 15027082 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate Plackett-Dale model for survival outcomes
Number of subjects: 0
Study 11504318 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (nortriptyline)
Number of subjects: 23
Study 11504318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 9133547 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethaphan (0.3-0.6 mg/min)
Number of subjects: 7
Study 9133547 — intervention group
Group type: COMPARATOR
Intervention: Regular human insulin (0.28 pmol x m(-2) x min(-1)) with variable rate glucose infusion
Number of subjects: 7
Study 8404789 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard breakfast
Number of subjects: 279
Study 8404789 — intervention group
Group type: COMPARATOR
Intervention: Fasting (no breakfast)
Number of subjects: 279
Study 8404789 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (breakfast and fasting)
Number of subjects: 279
Study 2419384 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy with cat- and dog-dander extracts
Number of subjects: 40
Study 2419384 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study 30640216 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP
Number of subjects: 500
Study 29420073 — intervention group
Group type: EXPERIMENTAL
Intervention: 380 mg intramuscular injections of long‐acting naltrexone on study day 1 and at the start of study week 5
Number of subjects: 12
Study 29420073 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study 25602170 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent Behavioral Activation Program (A-BAP)
Number of subjects: 60
Study 25602170 — intervention group
Group type: COMPARATOR
Intervention: Uncontrolled evidenced-based practice for depression
Number of subjects: 60
Study 21674691 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential finger tapping task
Number of subjects: 0
Study 21674691 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomly ordered finger-tapping task
Number of subjects: 0
Study 21674691 — intervention group
Group type: EXPERIMENTAL
Intervention: Selectivity index
Number of subjects: 0
Study 19413822 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cannula oxygen administration at 2 l x min(‐1)
Number of subjects: 13
Study 19413822 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cannula oxygen administration at 4 l x min(‐1)
Number of subjects: 13
Study 19413822 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cannula oxygen administration at 6 l x min(‐1)
Number of subjects: 13
Study 19413822 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal cannula oxygen administration at all flow rates
Number of subjects: 13
Study 17554647 — intervention group
Group type: EXPERIMENTAL
Intervention: Early colonoscopy
Number of subjects: 86
Study 17554647 — intervention group
Group type: COMPARATOR
Intervention: Late colonoscopy
Number of subjects: 86
Study 15865530 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game practicing (group B)
Number of subjects: 11
Study 15865530 — intervention group
Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 11
Study 12100641 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual pressure applied before intramuscular injection for 10 seconds
Number of subjects: 74
Study 12100641 — intervention group
Group type: COMPARATOR
Intervention: Conventional injection without manual pressure
Number of subjects: 74
Study 9707377 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 199
Study 9707377 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 199
Study 7883836 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (2 mg, orally)
Number of subjects: 18
Study 7883836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1298937 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound
Number of subjects: 56
Study 1298937 — intervention group
Group type: COMPARATOR
Intervention: Upper GI series
Number of subjects: 56
Study 1298937 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound negative and X-ray positive
Number of subjects: 56
Study 6380254 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg sublingual)
Number of subjects: 10
Study 6380254 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 10
Study 6380254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30783704 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up (n=50)
Number of subjects: 100
Study 30783704 — intervention group
Group type: COMPARATOR
Intervention: In-person clinic visits (n=50)
Number of subjects: 100
Study 30783704 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 29680872 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine 0.7%
Number of subjects: 2
Study 29680872 — intervention group
Group type: COMPARATOR
Intervention: Olopatadine 0.2%
Number of subjects: 2
Study 26891655 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored movement control exercise intervention (MC)
Number of subjects: 106
Study 26891655 — intervention group
Group type: COMPARATOR
Intervention: General exercise intervention (GE)
Number of subjects: 106
Study 24293165 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (200 mg daily) for 3 months followed by amiodarone for 15 months
Number of subjects: 51
Study 24293165 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 15 months
Number of subjects: 51
Study 24293165 — intervention group
Group type: COMPARATOR
Intervention: Control group (9 untreated patients undergoing ECV)
Number of subjects: 51
Study 22434466 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated tibial components
Number of subjects: 291
Study 22434466 — intervention group
Group type: COMPARATOR
Intervention: Cemented components
Number of subjects: 291
Study 20074810 — intervention group
Group type: EXPERIMENTAL
Intervention: First depressive episode
Number of subjects: 267
Study 20074810 — intervention group
Group type: EXPERIMENTAL
Intervention: Second depressive episode
Number of subjects: 267
Study 20074810 — intervention group
Group type: EXPERIMENTAL
Intervention: First recovery period
Number of subjects: 267
Study 20074810 — intervention group
Group type: EXPERIMENTAL
Intervention: Second recovery period
Number of subjects: 267
Study 18164527 — intervention group
Group type: EXPERIMENTAL
Intervention: Older group (aged adults)
Number of subjects: 0
Study 18164527 — intervention group
Group type: EXPERIMENTAL
Intervention: Proverb comprehension task
Number of subjects: 0
Study 16446685 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (40 g protein/day)
Number of subjects: 18
Study 16446685 — intervention group
Group type: COMPARATOR
Intervention: Whey protein (40 g protein/day)
Number of subjects: 18
Study 14609102 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% ointment applied twice daily for 21 days
Number of subjects: 23
Study 14609102 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (corresponding vehicle ointment)
Number of subjects: 23
Study 14609102 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol 0.005% ointment
Number of subjects: 23
Study 14609102 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol-17-propionate 0.05% ointment
Number of subjects: 23
Study 10576237 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 10576237 — intervention group
Group type: EXPERIMENTAL
Intervention: TAM 10 mg/day
Number of subjects: 43
Study 10576237 — intervention group
Group type: EXPERIMENTAL
Intervention: TAM 20 mg/day
Number of subjects: 43
Study 7851682 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion at rates of 0.25, 1.0, and 10.0 mU.kg‐1.min‐1 in donor subjects
Number of subjects: 24
Study 7851682 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycaemic clamp during insulin infusion in donor subjects
Number of subjects: 24
Study 7851682 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal model technique for insulin sensitivity and glucose effectiveness in donor subjects
Number of subjects: 24
Study 7851682 — intervention group
Group type: COMPARATOR
Intervention: Control subjects maintained at euglycaemia
Number of subjects: 24
Study 7851682 — intervention group
Group type: COMPARATOR
Intervention: Control subjects during hyperglycaemic clamp
Number of subjects: 24
Study 7851682 — intervention group
Group type: COMPARATOR
Intervention: Control subjects using minimal model technique
Number of subjects: 24
Study 2671283 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFVP (combination cyclophosphamide 60 mg/m2 orally every day for 1 year; fluorouracil 300 mg/m2 IV weekly for 1 year; methotrexate 15 mg/m2 IV weekly for 1 year; vincristine 0.625 mg/m2 IV for 10 weeks; prednisone 30 mg/m2 orally days 1 to 14, 20 mg/m2 days 15 to 28, 10 mg/m2 days 29 to 42)
Number of subjects: 441
Study 2671283 — intervention group
Group type: COMPARATOR
Intervention: L‐PAM (single‐agent melphalan 5 mg/m2 orally every day for 5 days every 6 weeks for 2 years)
Number of subjects: 441
Study 2671283 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFVP
Number of subjects: 441
Study 2671283 — intervention group
Group type: COMPARATOR
Intervention: L‐PAM
Number of subjects: 441
Study 339787 — intervention group
Group type: EXPERIMENTAL
Intervention: fenoterol (0.4 mg t.i.d. or q.i.d.)
Number of subjects: 44
Study 339787 — intervention group
Group type: COMPARATOR
Intervention: isoproterenol (0.15 mg t.i.d. or q.i.d.)
Number of subjects: 44
Study 31833059 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour maintenance dose of magnesium sulfate (MgSO4)
Number of subjects: 80
Study 31833059 — intervention group
Group type: COMPARATOR
Intervention: 24-hour maintenance dose of magnesium sulfate (MgSO4)
Number of subjects: 80
Study 30900158 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivestym (PF-06881893) 5 μg/kg subcutaneously as a single injection
Number of subjects: 340
Study 30900158 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivestym (PF-06881893) 5 μg/kg subcutaneously as five consecutive daily injections
Number of subjects: 340
Study 30900158 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivestym (PF-06881893)
Number of subjects: 340
Study 30900158 — intervention group
Group type: COMPARATOR
Intervention: US-Neupogen (filgrastim)
Number of subjects: 340
Study 28670132 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally laparoscopic aortobifemoral bypass surgery
Number of subjects: 50
Study 28670132 — intervention group
Group type: COMPARATOR
Intervention: Open aortobifemoral bypass surgery
Number of subjects: 50
Study 25775741 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide-awake technique with adrenaline-contained lidocaine (no tourniquet applied)
Number of subjects: 60
Study 25775741 — intervention group
Group type: COMPARATOR
Intervention: Conventional group with lidocaine (no adrenaline) and a 250-mmHg tourniquet application
Number of subjects: 60
Study 24170534 — intervention group
Group type: EXPERIMENTAL
Intervention: Research abstracts
Number of subjects: 0
Study 24170534 — intervention group
Group type: COMPARATOR
Intervention: Full-text manuscripts access
Number of subjects: 0
Study 22065870 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training programme (ETP) with 36 structured gym-based 1 hour sessions over 24 weeks, tailored to exercise capacity including aerobic, resistance, and balance exercises.
Number of subjects: 350
Study 22065870 — intervention group
Group type: COMPARATOR
Intervention: Control group DMP includes individualized education and follow-up from a multidisciplinary heart failure team; a weekly education programme for 12 weeks; self-management advice; and medical follow-up.
Number of subjects: 350
Study 18805773 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac-orphenadrine infusion (Group A)
Number of subjects: 60
Study 18805773 — intervention group
Group type: COMPARATOR
Intervention: Tramadol (Group B)
Number of subjects: 60
Study 18805773 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac-orphenadrine and tramadol (Group C)
Number of subjects: 60
Study 16599097 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraphat (fluoride varnish)
Number of subjects: 48
Study 16599097 — intervention group
Group type: EXPERIMENTAL
Intervention: SuperSeal (oxalate preparation)
Number of subjects: 48
Study 16599097 — intervention group
Group type: COMPARATOR
Intervention: Duraphat
Number of subjects: 48